Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Aptevo Therapeutics Trading Up 2.7 %

Shares of APVO opened at $0.36 on Tuesday. The stock has a 50 day moving average price of $0.38 and a 200 day moving average price of $1.80. Aptevo Therapeutics has a one year low of $0.28 and a one year high of $21.56.

Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.26. Equities analysts anticipate that Aptevo Therapeutics will post -4.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities & Exchange Commission. 8.06% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.